Send us Fan Mail

We sit down with hematology nurse practitioner Maya Bloomberg to cut through the noise around hemophilia gene therapy, including what it can realistically change and what it cannot. We talk durability, safety, access, and the human side of decision-making so patients and families can walk into care feeling informed and empowered. 

• what gene therapy aims to do in hemophilia and why “cure” can mislead 
• how factor levels can rise, vary widely, and decline over time 
• eligibility basics, including AAV antibody testing and why redosing is limited 
• liver toxicity risk, frequent lab monitoring, and steroid protocols after infusion 
• lifestyle constraints, including the recommendation for no alcohol 
• family planning considerations, including viral shedding in semen and timing for conception 
• why gene therapy does not stop hemophilia from being passed to children 
• identity and belonging fears and how comprehensive HTCs support psychosocial needs 
• access gaps in community hospitals and why establishing HTC care early matters 
• telehealth options and decision tools, including WFH resources and Zebra for Care 
• women carriers with real bleeding symptoms, delayed diagnosis, and the need to advocate 

I would encourage everyone to complete the five-minute simple assessment at hematology.zebraforcare.com

Make sure to subscribe and stay connected with the group of extraordinary achievers and pioneers.

Thanks for tuning into the HemoLife Podcast. Be sure to subscribe, leave a review, and share this episode with someone who needs a spark of hope or encouragement. Follow us on Instagram @HemoLife_Podcast and YouTube for updates, guest highlights, and behind-the-scenes content. New episodes drop regularly—your story matters, and this is just the beginning.